Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03138499 · ClinicalTrials.gov registry record · Phase 3
A Study of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage Classical Hodgkin Lymphoma, Who Are Relapsed/ Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant,
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Terminated
- Registry status
- Phase 3
- Development phase
- 23
- Enrollment target
NCT03138499 is a Phase 3 study that was terminated before completion, run by Bristol-Myers Squibb. The registered enrollment target is 23 participants.
The verdict
NCT03138499, a Phase 3 study, was terminated before completion, sponsored by Bristol-Myers Squibb.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 23 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether an investigational immuno-therapy combination, nivolumab with Brentuximab vedotin compared to Brentuximab vedotin alone is safe and effective in the treatment of relapsed and refractory Classical Hodgkin Lymphoma. The participants of this trial will comprise of patients who have relapsed or did not respond to treatment and are not eligible for stem cell transplant
Interventions
- BIOLOGICAL Nivolumab
- BIOLOGICAL Brentuximab vedotin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2017-06-26 |
| Est. Completion | 2021-02-22 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03138499
The ClinicalTrials.gov registry entry for NCT03138499 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nivolumab is the first listed.
NCT03138499 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03138499 about?
NCT03138499 is a clinical study titled "A Study of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage Classical Hodgkin Lymphoma, Who Are Relapsed/ Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant,". The purpose of this study is to determine whether an investigational immuno-therapy combination, nivolumab with Brentuximab vedotin compared to Brentuximab vedotin alone is safe and effective in the treatment of relapsed and refractory Classical Hodgkin Lymphoma. The participants of this trial will ...
What is the current status of trial NCT03138499?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 23 participants. The study started on 2017-06-26. Estimated completion is 2021-02-22.
What interventions are being tested in trial NCT03138499?
The interventions under investigation include: Nivolumab (BIOLOGICAL), Brentuximab vedotin (BIOLOGICAL).
Who is sponsoring clinical trial NCT03138499?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.